US Patent

US12478606 — Methods of treating bacterial infections

Method of Use · Assigned to Melinta Subsidiary Corp · Expires 2038-01-08 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Methods are disclosed for treating urinary tract infections, including complicated urinary tract infections and acute pyelonephritis, using a combination of vaborbactam and meropenem.

USPTO Abstract

Methods of treating or ameliorating urinary tract infection (UTI), including complicated urinary tract infection (cUTI) and acute pyelonephritis (AP), comprising administering a composition comprising a cyclic boronic acid ester vaborbactam in combination with meropenem are disclosed herewith.

Drugs covered by this patent

Merrem (Meropenem) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3421`	—	Merrem

Patent Metadata

Patent number: US12478606
Jurisdiction: US
Classification: Method of Use
Expires: 2038-01-08
Drug substance claim: No
Drug product claim: No
Assignee: Melinta Subsidiary Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.